122 related articles for article (PubMed ID: 6141691)
1. The glucagonoma syndrome: stimulus-induced plasma responses of circulating glucagon components IRG9000 and IRG3500.
Hendriks T; Jansen JB; van Tongeren JH
Acta Endocrinol (Copenh); 1984 Feb; 105(2):226-32. PubMed ID: 6141691
[TBL] [Abstract][Full Text] [Related]
2. Plasma glucagon-immunoreactive components in early life in dogs.
Ghiglione M; Pascual JM; Rovira A; Calvo G; Valverde I
Horm Metab Res; 1985 Aug; 17(8):387-90. PubMed ID: 2865202
[TBL] [Abstract][Full Text] [Related]
3. Immunologic characterization of plasma glucagon components in a patient with malignant glucagonoma.
Tanaka K; Watabe T; Shimizu N; Horiuchi T; Nakamura K; Yoshida H
Metabolism; 1984 Aug; 33(8):728-33. PubMed ID: 6087085
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical elevations of plasma glucagon levels in patients after pancreatectomy or gastrectomy.
Ohtsuka K; Nimura Y; Yasui K
Jpn J Surg; 1986 Jan; 16(1):1-7. PubMed ID: 3959356
[TBL] [Abstract][Full Text] [Related]
5. A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome.
Fujita J; Seino Y; Ishida H; Taminato T; Matsukura S; Horio T; Imamura S; Naito A; Tobe T; Takahashi K
Cancer; 1986 Feb; 57(4):860-5. PubMed ID: 2867823
[TBL] [Abstract][Full Text] [Related]
6. Secretory response and immunochemical heterogeneity of glucagon in plasma and tumor extracts of a patient with glucagonoma.
Torre L; Vazquez JA; Blázquez E
Horm Res; 1986; 23(3):159-66. PubMed ID: 3005153
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.
Kuku SF; Jaspan JB; Emmanouel DS; Zeidler A; Katz AI; Rubenstein AH
J Clin Invest; 1976 Sep; 58(3):742-50. PubMed ID: 956399
[TBL] [Abstract][Full Text] [Related]
8. Plasma immunoreactive glucagon fractions in four cases of glucagonoma: increased "large glucagon-immunoreactivity".
Recant L; Perrino PV; Bhathena SJ; Danforth DN; Lavine RL
Diabetologia; 1976 Aug; 12(4):319-26. PubMed ID: 183997
[TBL] [Abstract][Full Text] [Related]
9. Immunoreactive glucagon in nondiabetic and diabetic Macaca nigra.
Howard CF; Van Bueren A
Horm Metab Res; 1981 Apr; 13(4):203-6. PubMed ID: 7239433
[TBL] [Abstract][Full Text] [Related]
10. Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma.
Valverde I; Lemon HM; Kessinger A; Unger RH
J Clin Endocrinol Metab; 1976 May; 42(5):804-8. PubMed ID: 178682
[TBL] [Abstract][Full Text] [Related]
11. Glucagonoma syndrome.
Hashizume T; Kiryu H; Noda K; Kano T; Nakano R
J Am Acad Dermatol; 1988 Aug; 19(2 Pt 2):377-83. PubMed ID: 2842381
[TBL] [Abstract][Full Text] [Related]
12. Effects of somatostatin on insulin and glucagon in patients with insulinoma.
Fallucca F; Mirabella C; Tamburrano G; Gambardella S; Aufieri G; Barbetti F; Andreani D
J Endocrinol Invest; 1979; 2(3):257-60. PubMed ID: 231062
[TBL] [Abstract][Full Text] [Related]
13. Excessive circulating large molecular weight immunoreactive glucagon components in subjects with the idiopathic postprandial syndrome.
Charles MA; Waldeck N
J Clin Endocrinol Metab; 1981 Aug; 53(2):366-71. PubMed ID: 6265488
[TBL] [Abstract][Full Text] [Related]
14. Plasma glucagon in insulinoma.
Ohneda A; Matsuda K; Horigome K; Ishii S; Yanbe A; Maruhama Y
Acta Diabetol Lat; 1977; 14(5-6):219-28. PubMed ID: 207064
[TBL] [Abstract][Full Text] [Related]
15. Recurrent pheochromocytoma associated with glucagonoma. A case report.
Yao H; Fukiyama K; Kawano Y; Mizumoto K; Toyoshima S; Omae T
Endocrinol Jpn; 1983 Apr; 30(2):163-6. PubMed ID: 6139277
[TBL] [Abstract][Full Text] [Related]
16. Plasma glucagon and glucagon-like immunoreactive components in Type 1 (insulin-dependent) diabetic patients and normal subjects before and after an oral glucose load.
Rovira A; Garrote FJ; Pascual JM; Salvador MG; Herrera Pombo JL; Valverde I
Diabetologia; 1985 Feb; 28(2):80-6. PubMed ID: 3838521
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitory effects of somatostatin analog (SMS 201-995) on pancreatic hormones in patients with malignant islet-cell carcinoma].
Fukushima H; Ueno S; Sakakida M; Takahashi T; Shirotani T; Araki E; Kishikawa H; Yamaguchi K; Nakamura N; Uzawa H
Nihon Naibunpi Gakkai Zasshi; 1988 Aug; 64(8):666-76. PubMed ID: 2852126
[TBL] [Abstract][Full Text] [Related]
18. [Glucagonoma syndrome with normal blood glucagon ].
Quencez E; Zultak M; Blanc D; Gillet M; Laurent R
Ann Dermatol Venereol; 1987; 114(9):1103-8. PubMed ID: 2829690
[No Abstract] [Full Text] [Related]
19. A case with glucagonoma syndrome--endocrine and metabolic studies.
Fukushima H; Yamaguchi K; Uzawa H; Kitoh M; Takemiya M; Konno T
Endocrinol Jpn; 1981 Apr; 28(2):111-25. PubMed ID: 6273136
[TBL] [Abstract][Full Text] [Related]
20. Glucagon immunoreactivity and antidiabetic action of somatostatin in the totally duodeno-pancreatectomized and gastrectomized human.
Bringer J; Mirouze J; Marchal G; Pham TC; Luyckx A; Lefebvre P; Orsetti A
Diabetes; 1981 Oct; 30(10):851-6. PubMed ID: 6115786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
